Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO 2015

“We’re particularly excited about our data in different types of advanced lung cancer, including pivotal data for alectinib and results of the first randomised study of our investigational immunotherapy, MPDL3280A,” said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head, Global Product Development. “These results build upon our long-standing commitment to improve outcomes for people with lung cancer, and we hope these data will help us bring new options to treat this devastating disease.”

Data presented at ASCO 2015 for alectinib and Gazyva/Gazyvaro will support submissions for marketing authorisation

Updated results from studies of cobimetinib in combination with Zelboraf in advanced BRAF-mutated melanoma will be presented during ASCO 2015. Cobimetinib is currently under review with both the US Food and Drug Administration (FDA) and the European Medicines Agency.

Data presented at ASCO 2015 for alectinib in advanced non-small-cell lung cancer (NSCLC) and Gazyva/Gazyvaro in indolent non-Hodgkin’s Lymphoma will support submissions for marketing authorisation.

For MPDL3280A, an investigational cancer immunotherapy for advanced NSCLC, Roche is discussing interim data from POPLAR, the large, randomised Phase II study with the FDA as part of its Breakthrough Therapy Designation in lung cancer. Preliminary data will also be presented on investigational medicine venetoclax in non-Hodgkin’s lymphoma and multiple myeloma. The FDA recently granted Breakthrough Therapy Designation to venetoclax for people with relapsed/refractory chronic lymphocytic leukaemia who have a genetic abnormality known as 17p deletion.

For more information about Roche, please visit www.roche.com.